DexCom showed strong growth, margin expansion, and Stelo's OTC launch unlocked new markets despite competitive and regulatory ...

DexCom, Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy and hold forever. On September 22, UBS reiterated a ‘Buy’ ...

The Food and Drug Administration has granted de novo classification to a continuous glucose monitor made by Biolinq for ...

Investing.com - UBS maintained its Buy rating and $106.00 price target on DexCom (NASDAQ:DXCM) following a Friday sell-off triggered by concerns about the company’s G7 continuous glucose monitoring ...

Next presentation this afternoon is from DexCom, a leader in developing and commercializing continuous glucose monitoring systems for people with diabetes and I'm sure in the future beyond diabetes.

Shares of DexCom (NASDAQ:DXCM) fell for the third straight session on Friday to reach the lowest level since April, even as ...

The FDA said Dexcom issued a correction for certain continuous glucose monitor apps due to a software design error that ...

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include ...

ViCentra's Kaleido is "the smallest, thinnest, lightest, most precise insulin patch pump in its class," CEO Tom Arnold said ...

The San Diego-based company claims a number of firsts for its coin-sized Biolinq Shine device, including that it is so far ...

UBS analyst Danielle Antalffy reiterated a Buy rating on Dexcom today and set a price target of $106.00. The company’s shares opened today at $67.69. Take advantage of TipRanks Premium at 50% off!